DUBLIN, October 27, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Cervical Cancer Forecast in 22 Major Markets 2016-2026" report to their offering.
Cervical cancer (ICD-10 code C53, cervix uteri) is a type of cancer that occurs in the cells of the cervix. Cervical cancer is generally preceded by Cervical Intraepithelial Neoplasia (CIN).
Nearly all cervical cancer cases (>90%) have been linked with HPV infection, with identification of 14 high-risk HPV (hrHPV) genotypes linked to cervical cancer.
Typically, squamous cells lining the cervix respond to exposure to HPV infection, causing them to replicate. The extent of abnormal growth (in the pre-cancerous phase) is the basis for CIN grading, from 1 to 3, where 3 represents disorganisation through the full extent of then epithelial layer.
This report provides the current incident population for Cervical Cancer across 22 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Netherlands, Poland, Romania, Russia, Turkey, Australia, Japan, South Korea, China, India, Argentina, Brazil, Mexico, South Africa and Saudi Arabia) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Cervical Cancer have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
The following conditions are associated with cervical cancer:
- Infection with HPV genotypes 16 & 18
- Unprotected sex
- Extended use of oral contraceptives
- Impaired immunity
Key Topics Covered:
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key comorbid conditions/Features associated with the disease
8. Methodology for quantification of patient numbers
9. Top-line prevalence for Cervical Cancer
10. Stage of Cervical Cancer patients
11. Histopathology of Cervical Cancer patients
12. Abbreviations used in the report
13. Patient-Based Offering
14. Online Pricing Data and Platforms
For more information about this report visit http://www.researchandmarkets.com/research/j86pqd/cervical_cancer
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets